Ethyol has been approved to reduce the renal toxicity associated with repeated administration of chemotherapy in subjects with advanced ovarian cancer. Currently, there are only limited data on the effects of Ethyol on the efficacy of chemotherapy in other settings. Ethyol should not be administered to patients receiving chemotherapy for malignancies that are commonly curable, except in the context of a clinical study.
Pretreatment with Ethyol significantly reduced the cumulative renal toxicity associated with multiple cycles of chemotherapy.
The most common adverse effects of Ethyol were vomiting, low blood pressure, somnolence, and sneezing. Vomiting, hypotension, and somnolence were more common with higher drug doses. In a phase I trial, vomiting and somnolence were experienced significantly more frequently by women than men.
The Ethyol (amifostine) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.